If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Serious side effects that are rare (may affect up to 1 in 1,000 people) or very rare (may affect up to 1 in 10,000 people) could be severe: seek medical help immediately.
If you experience any of these side effects, inform your doctor immediately.
Other side effects: inform your doctor if you are concerned.
Frequent (may affect up to 1 in 10 people):
Difficulty sleeping, headache, stomach discomfort, abdominal pain, nausea, altered muscle and liver parameters in blood tests.
Very rare (may affect up to 1 in 10,000 people):
Tickling or numbness of the hands or feet, altered or decreased sensitivity.
Unknown (frequency cannot be estimated from available data):
Other possible side effects:
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy.Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Fluvastatina STADA
Each prolonged-release tablet contains 80 mg of fluvastatin (as fluvastatin sodium).
- Tablet core: povidone, microcrystalline cellulose, hydroxyethylcellulose, mannitol, magnesium stearate.
- Tablet coating: hypromellose 50, macrogol 6000, yellow iron oxide (E172), titanium dioxide (E171).
Appearance of the product and content of the container
Fluvastatina STADA are biconvex, round, and yellow prolonged-release tablets.
Container size:
Blister (OPA/Al/PVC-Al): 7, 20, 28, 30, 50, 56, 98, 100, and 120 prolonged-release tablets.
Only some container sizes may be commercially marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern
(Barcelona)
Responsible for manufacturing:
Actavis Ltd.
BLB016, Belebel Industrial Estate,
Zejtun ZTN 3000
Malta
or
Actavis ehf.
Reykjavikurvegi 78,
IS-222 Hafnarfjordur
Islandia
or
STADA Arzneimittel AG
Stadastrasse 2-18, 61118 Bad Vilbel
Alemania
Last review date of this leaflet: October 2018
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.